Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Wrong potency or content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk.

992 FDA drug recalls with this cause, newest first.

These recalls cover sub-potent or super-potent products, or a failed content-uniformity test - meaning some pills in the same batch held noticeably different amounts of active ingredient than others. Either way it is a direct dosing risk: too little to work, or too much and harmful. Thyroid hormones and compounded injectables are the classic examples, because their dose window is narrow.

Class II · Moderate risk

CAREone

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

Ongoing Wrong potency / content Bell Pharmaceuticals, Inc NDC 72476-838-34 D-0688-2026
Class II · Moderate risk

meijer

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

Ongoing Wrong potency / content Bell Pharmaceuticals, Inc NDC 41250-835-33 D-0687-2026
Class II · Moderate risk

Foster & Thrive

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

Ongoing Wrong potency / content Bell Pharmaceuticals, Inc NDC 70677-1154-01 D-0686-2026
Class II · Moderate risk

Leader

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

Ongoing Wrong potency / content Bell Pharmaceuticals, Inc NDC 70000-0689-1 D-0685-2026
Class II · Moderate risk

Good Neighbor Pharmacy

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

Ongoing Wrong potency / content Bell Pharmaceuticals, Inc NDC 46122-556-05 D-0684-2026
Class II · Moderate risk

FAMILY Wellness

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

Ongoing Wrong potency / content Bell Pharmaceuticals, Inc NDC 55319-835-01 D-0683-2026
Class II · Moderate risk

Audiologist's Choice

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

Ongoing Wrong potency / content Bell Pharmaceuticals, Inc NDC 59256-001-02 D-0682-2026
Class II · Moderate risk

TopCare Health

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

Ongoing Wrong potency / content Bell Pharmaceuticals, Inc NDC 36800-835-33 D-0681-2026
Class II · Moderate risk

QC Quality Choice

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

Ongoing Wrong potency / content Bell Pharmaceuticals, Inc NDC 63868-026-15 D-0680-2026
Class II · Moderate risk

Clinere

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

Ongoing Wrong potency / content Bell Pharmaceuticals, Inc NDC 68229-102-01 D-0679-2026
Class II · Moderate risk

CVS Health

SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).

Ongoing Wrong potency / content Bell Pharmaceuticals, Inc NDC 51316-822-00 D-0678-2026
Class II · Moderate risk

Nystatin Cream USP

Subpotent Drug: Low out of specification assay results performed during long-term stability testing.

Ongoing Wrong potency / content Padagis US LLC NDC 45802-059-35 D-0677-2026